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Abstract
Testicular germ cell tumors (TGCT) are the most frequently diagnosed solid tumors in young men 
ages 15 to 44 years. Embryonal carcinomas (EC) comprise a subset of TGCTs that exhibit 
pluripotent characteristics similar to embryonic stem (ES) cells, but the genetic drivers underlying 
malignant transformation of ECs are unknown. To elucidate the abnormal genetic events 
potentially contributing to TGCT malignancy, such as the existence of fusion genes or aberrant 
fusion transcript expression, we performed RNA sequencing of EC cell lines and their non-
malignant ES cell line counterparts. We identified eight novel fusion transcripts and one gene with 
alternative promoter usage, ETV6. Four out of nine transcripts were found recurrently expressed in 
an extended panel of primary TGCTs and additional EC cell lines, but not in normal parenchyma 
of the testis, implying tumor-specific expression. Two of the recurrent transcripts involved an 
intrachromosomal fusion between RCC1 and HENMT1 located 80 Mbp apart and an 
interchromosomal fusion between RCC1 and ABHD12B. RCC1-ABHD12B and the ETV6 
transcript variant were found to be preferentially expressed in the more undifferentiated TGCT 
subtypes. In vitro differentiation of the NTERA2 EC cell line resulted in significantly reduced 
expression of both fusion transcripts involving RCC1 and the ETV6 transcript variant, indicating 
that they are markers of pluripotency in a malignant setting. In conclusion, we identified eight 
novel fusion transcripts that, to our knowledge, are the first fusion genes described in TGCT and 
may therefore potentially serve as genomic biomarkers of malignant progression.
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Introduction
Testicular germ cell tumors (TGCTs) are the most common cancer in young men ages 15-44 
years (1). Although it is a highly treatable cancer type, exemplified by a 10-year net survival 
rate of 98 % in England and Wales (2), the disease affects men in their prime and treatment 
can lead to substantially increased morbidity, including cardiovascular disease, reduced 
fertility and secondary cancers (3). Histologically, there are two main subtypes of TGCTs, 
seminomas and non-seminomas. Both are thought to develop from the pre-invasive stage 
termed intratubular germ cell neoplasia (IGCN; also known as carcinoma in situ). Non-
seminomas are further divided into the pluripotent embryonal carcinomas (EC) and more 
differentiated subtypes, with either somatic (teratoma) or extra-embryonic differentiation 
(yolk sac tumors, YST, and choriocarcinomas)(4).
EC cells are highly similar to embryonic stem (ES) cells, derived from the inner cell mass of 
the blastocyst stage embryo (5). Both cell types exhibit pluripotent characteristics 
phenotypically and in gene expression profiles (6,7). Upon extended passaging in vitro, ES 
cells have been shown to acquire genetic changes similar to those seen in malignant 
transformation in vivo of TGCTs and EC, including gain of genetic material from 
chromosomes 12, 17, and X (8). Gain of chromosome arm 12p, often as an isochromosome, 
i(12p), is found in virtually all cases of TGCT (9,10). Crucially, despite these similarities, 
EC cells are malignant in character, whereas ES cells are not. Comparative studies between 
the two cell types may therefore be useful for characterization of cancer-specific differences 
in a pluripotent context (5,11). One such study revealed that several transcription factors 
located on 12p are overexpressed in EC cells as compared to ES cells (6). Although 12p 
material is gained in virtually all cases of TGCT, no clear genetic driver for TGCT 
malignant transformation has been pinpointed (12,13).
Recently, whole-exome sequencing studies have revealed that the number of non-
synonymous mutations in coding regions of the TGCT genome are few, on a scale similar to 
that of pediatric cancers (14–16). A number of pediatric cancers with a low mutational load 
are frequently found to harbor fusion genes with oncogenic properties. Examples are MLL 
rearrangements in acute lymphoblastic leukemia (17), and subtypes of sarcomas classified 
by distinct chromosomal translocations (18). In Ewing sarcoma, fusions involving EWSR1 
are pathognomonic, while the mutation rate is low, estimated at 0.15/Mb of coding sequence 
(19). In this study, we have performed RNA sequencing of EC cell lines and their non-
malignant counterpart, ES cell lines. Application of a fusion gene analysis pipeline led to the 
identification of nine novel fusion genes and transcripts, to our knowledge the first described 
in TGCT.
Material and Methods
Cell lines and patient samples
Three EC cell lines (2102Ep, 833KE, and NTERA2) and 2 ES cell lines (H9 and Shef3) 
were subjected to RNA sequencing. The EC and ES cell lines were established in the lab of 
Peter W. Andrews, University of Sheffield, where they also were grown and sorted for 
expression of the pluripotency marker SSEA3 as previously described (11). The extended 
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experimental validation panel consisted of four categories of samples: 1) 2 additional EC 
(Tera 1 and NCCIT) and 2 additional ES (Shef6 and Shef7) cell lines (n=4), 2) NTERA2 and 
2102Ep cells treated with all-trans retinoic acid (RA) for 0, 3 and 7 days to induce 
differentiation, as previously described (n=6) (20,21). 3) Thirty-five testicular tissue samples 
including 5 normal testicular parenchyma, 6 premalignant IGCN and 24 primary TGCTs, all 
with only one histological subtype each; EC (n=8), seminoma (n=7), choriocarcinoma (n=1), 
YST (n=4), and teratoma (n=4). 4) Twenty normal tissues from miscellaneous sites of the 
body were used for exploration of cancer-specificity of the novel transcripts (adipose, 
bladder, brain, cervix, colon, esophagus, heart, kidney, liver, lung, ovary, placenta, prostate, 
skeletal muscle, spleen, stomach, testes, thymus, thyroid and trachea; FirstChoice Human 
Normal Tissue Total RNA). These were each a pool of RNA from at least three individuals, 
with the exception of one individual sample from the stomach (Ambion, Applied 
Biosystems by Life Technologies, Carlsbad, CA, USA).
DNA isolated simultaneously from the cell pellets was tested and authenticated by STR 
fingerprinting using the AmpFLSTR Identifiler PCR Amplification Kit (Applied 
Biosystems). Profiles positively matched with those reported in the literature for 2102Ep (7), 
and obtained from the European Collection of Cell Cultures (ECACC; for 833KE), ATCC 
(for NTERA2, NCCIT, and TERA1), the Wisconsin International Stem Cell Bank (H9), and 
the UK Stem Cell Bank (Shef3, Shef6, and Shef7). The biobank is registered according to 
Norwegian legislation (no. 953; Biobank Registry of Norway) and the project has been 
approved by the National Committee for Medical and Health Research Ethics (S-05368 and 
S-07453b).
External data for in silico validation
Paired-end RNA sequencing data from the Illumina Human Body Map v2 dataset, consisting 
of 16 non-malignant miscellaneous tissue types, was analyzed as an additional source of 
normal controls (ArrayExpress accession ID E-MTAB-513 and European Nucleotide 
Archive study accession ID ERP000546).
Paired end RNA-sequencing of EC and ES cell lines
Library construction was performed using the standard Illumina mRNA library preparation 
protocol (Illumina Inc, San Diego, CA, USA), including poly-A mRNA isolation, 
fragmentation, and gel-based size selection. Shearing to about 250 bp fragments was 
achieved using the Covaris S2 focused ultrasonicator (Covaris Inc, Woburn, MA, USA). 
Paired-end sequencing, 76 bp from each end, was performed according to protocol on a 
Genome Analyzer IIx (Illumina Inc.).
Fusion transcript identification
To identify fusion transcripts specific for EC, we used the fusion detection algorithm deFuse 
v. 0.6.1 (22) with hg19 sequence reference from UCSC and Ensembl release 69 annotation. 
To enrich for true positive fusion transcripts specifically expressed in EC cells, several 
heuristic filtering steps of the initial fusion breakpoint candidates were performed, some 
adapted from the recommended procedures of the original publication of deFuse (22), 
namely: 1) Only the nominated fusion breakpoint candidates with a probability score greater 
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than 0.5 were considered. 2) Breakpoints nominated in EC that were also found in ES cell 
lines or tissues of the Human Body Map v2 were removed to enrich for malignancy-specific 
candidates and remove systematic technical artifacts. 3) We removed candidates that had 
more than 5 multi-mapping spanning reads, or a ratio of multi-mapping spanning reads 
greater than 25 %. 4) To filter out candidates nominated due to homologous or repeat 
sequences, we removed candidates that had a deFuse homology score greater than 10 and 
candidates having either of the following three criteria: cDNA adjusted-, genome adjusted- 
or EST adjusted percent identity greater than 0.1. In an effort to enrich for functionally 
interesting fusion candidates, we applied 4 functional filters of which candidates needed to 
pass 3 in order to proceed. 1) Both gene partners are annotated as protein-coding genes. 2) 
The number of split reads and spanning reads supporting the fusion breakpoint sequence is 
greater than or equal to 3 or 5, respectively. 3) The fusion breakpoint includes 5′ UTR or 
coding parts of at least one of the partner genes. 4) The distance between the two partner 
genes is greater than 30 kb. We also used an additional fusion finder algorithm, SOAPfuse v.
1.26 (23), and included all fusion breakpoints that were picked up by both deFuse and 
SOAPfuse independently. For the remaining fusion transcripts, breakpoint alignments were 
evaluated in the UCSC genome browser and the Integrative Genomic Viewer (IGV). In 
general, we removed chimeric breakpoint sequences likely to derive from read-through 
transcripts, and those not aligning to conserved exon to exon boundaries.
Validation of fusion transcript breakpoints by reverse-transcriptase PCR and Sanger 
sequencing
Selected fusion transcript candidates were validated with reverse transcription PCR (RT-
PCR) in the RNA-sequenced cell lines and in an extended validation panel. Primers were 
designed to the fusion transcript breakpoint sequences as detected by deFuse by using the 
Primer3 web application (24). All primer sequences used in this study are listed in 
Supplementary Table S1. Briefly, reverse transcription was performed using the high-
capacity reverse transcription kit according to protocol (Applied Biosystems by Life 
Technologies, CA, USA). From 50 ng of starting cDNA template, a PCR protocol was 
initiated with 15 minutes of HotStarTaq DNA polymerase activation at 95°C, followed by 30 
thermal cycles of denaturation for 30 seconds at 95°C, primer annealing for 1 minute at 
optimal primer melting temperatures (Supplementary Table S1), and extension for one 
minute at 72°C. After the last cycle, a final extension step was performed at 72°C for 10 
minutes. The PCR products were separated by electrophoresis at 200 V for 30 minutes on a 
2 % agarose gel and visualized using ethidium bromide and UV light.
To ensure specific amplification of the breakpoint sequences, PCR products from the cell 
lines that were nominated by RNA-seq to harbor the individual fusion transcripts were 
sequenced by Sanger sequencing. PCR products that showed a single nucleotide band on the 
agarose gel were sequenced directly from both sides using forward and reverse primers. 
Prior to sequencing, the PCR products were purified using Illustra ExoStar 1-step cleanup 
(GE Healthcare, Little Chalfront, UK). The cycle sequencing reactions were performed 
using the BigDye Terminator v.1.1 cycle sequencing kit (Applied Biosystems, Foster City, 
CA, USA) following manufacturer’s recommendations. The sequencing products were 
purified using BigDye Xterminator (Applied Biosystems) before being analyzed by capillary 
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electrophoresis using the ABI 3730 DNA Analyzer (Applied Biosystems). The resulting 
sequences were analyzed using the Sequencing Analysis v.5.3.1 software.
The quantity of fusion transcripts assessed by TaqMan real-time PCR
Several fusion transcripts confirmed by regular RT-PCR were recurrent, however with 
varying nucleotide band intensities between samples, as observed by agarose gel 
electrophoresis. We performed TaqMan quantitative RT-PCR (qRT-PCR) to quantify the 
relative expression of these fusion transcripts. Primers and MGB-probes were designed with 
the Primer Express v.3.0 software (Applied Biosystems) to cross the fusion transcript 
boundaries (Supplementary Table S1). Two endogenous control assays targeting ACTB and 
GUSB were analyzed in all samples to normalize for input template amounts. The qRT-PCR 
reactions were performed in reaction volumes of 10 μl, with 15 ng of template cDNA, 
TaqMan universal mastermix II with uracil-N-glycosylase (Applied Biosystems) and final 
primer and probe concentrations of 0.9 μM and 0.2 μM, respectively. The PCR reactions 
were run in triplicate on an ABI 7900HT fast real-time PCR system (Applied Biosystems). 
Expression levels were reported as the median cycle threshold (CT) of the triplicates and 
normalized to median CT values of the endogenous controls. A threshold value at CT = 35 
was set for all assays as positive expression.
Assessment of DNA-level fusions with multiplexed droplet digital PCR
Droplet digital PCR (ddPCR) takes advantage of oil/water emulsion, separating PCR 
reagents and template into thousands of nano-liter sized droplets. Subsequent thermal 
cycling by traditional fluorescent PCR specifically amplifies target templates in the droplets. 
The number of target molecules in a reaction mixture is inferred by counting the number of 
droplets with and without amplified fluorescent signal. It is also possible to measure two 
target molecules simultaneously, by multiplexing 2 PCR assays with different fluorescent 
dyes (FAM and VIC/HEX). Since template molecules distribute randomly into droplets, 
droplets can be expected to contain one, the other, both or none of the target molecules by 
chance in a multiplexed assay. However, if two template targets are located in close 
proximity on the same DNA molecule and thereby linked, these would distribute together in 
a non-random fashion with a higher number of double positive droplets than expected by 
chance.
Here, we performed ddPCR to investigate DNA-level linkage of the partner genes of 2 
recurrent fusion transcripts, as well as 2 fusion transcripts that each were expressed only in 
one EC cell line. As proof of concept, we included duplex linkage assays for the known 
fusion VTI1A-TCF7L2, which in the NCI-H508 cell line is known to be formed by a 
genomic deletion (25). To evaluate the integrity of DNA fragments, and as an additional 
positive control of the ddPCR linkage approach, we used a custom milepost experiment 
which measures linkage with assays 1 kb, 10 kb, 50 kb and 100 kb apart. In all experiments, 
a reference assay with FAM fluorescence was multiplexed with one of the milepost assays 
with VIC fluorescence. FAM and VIC assays were also designed for the two partner genes 
of the fusion transcripts. All assays used in the ddPCR linkage experiments are listed in 
Supplementary Table S2. As control experiments for the linkage assays we performed 
fragmentation of genomic DNA with the NspI restriction endonuclease. We ensured that 
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none of the assay’s target sequences overlapped with the restriction enzyme target sequence. 
Each ddPCR experiment was carried out in 22 μl reaction volumes, with final concentrations 
of 0.9 μM of each primer and 0.25 μM probe, 1x ddPCR supermix (Bio-Rad) and 25 to 50 
ng genomic DNA. Droplet generation was performed with 20 μL of the reaction mix, 
according to the manufacturer’s protocol. Droplets were then transferred to a 96-well plate 
and PCR performed with the following thermal cycling profile: initial enzyme activation at 
95°C for 10 minutes, followed by 40 cycles of denaturation at 94°C for 30 seconds and 
annealing/extension at 60°C for 1 minute. As a final step, the enzyme was deactivated at 
98°C for 10 min. The droplets were read using the QX200 droplet reader according to 
manufacturer’s protocol. The data was analyzed using the QuantaSoft software (1.7.4.0917; 
Bio-Rad). Crosshair gating was used to set a threshold for the four quadrants of droplet 
populations: double-negative, FAM-positive, VIC-positive and double-positive. QuantaSoft 
outputs the concentration in molecules/μl for each of the assays. Additionally, a linkage 
concentration is calculated based on the ratio of double-positive droplets, given in linked 
molecules/μl. We calculated percent linkage as the concentration of linked molecules 
divided by the mean concentration of the individual assays transformed to percentage.
Results
Identification of fusion transcripts in EC cell lines from paired-end RNA-seq data
RNA sequencing of the three EC (2102Ep, 833KE, and NTERA2) and two ES (H9 and 
Shef3) cell lines generated a total of 199 million pairs of 76 bp sequencing reads that passed 
filtering (Supplementary Table S3).
Fusion transcript analyses of the RNA-seq data resulted in an initial list of 1210 unique 
fusion breakpoints with a probability score above 0.5. Subsequent heuristic filtering 
nominated nine fusion transcripts which were considered strong enough for further 
experimental validation (Figure 1). Briefly, 283 candidate fusions were first removed as they 
were also detected in ES cell lines or normal human tissues (i.e. external data from the 
Illumina Human Body Map v2 data set). Further technical filtering of fusion breakpoints 
with a high ratio of multi-mapping spanning reads and breakpoints with a high degree of 
homology or breakpoint sequence identity, removed 621 and 130 candidates respectively. To 
enrich for functionally important breakpoints, we removed breakpoints that did not pass at 
least three out of four functional filters. As an additional step, we used the SOAPfuse fusion 
finder to identify a list of 85 potential EC fusion breakpoint candidates. Of these, only 11 
overlapped with the initial list of EC specific breakpoints generated by deFuse, where five of 
these were already kept through the filtering process. The remaining six overlapping 
candidates were retrieved for evaluation in the final candidate list. After filtering steps, a list 
of 65 unique candidate fusion breakpoints remained, and was manually curated by viewing 
alignments in IGV and the UCSC genome browser. Fusion transcripts likely to be generated 
by polymerase read-through were filtered out, except for a read-through between CLEC6A 
and CLEC4D located on chromosome arm 12p found to be recurrent in all three EC cell 
lines. Fusion candidates where the breakpoint did not match intact conserved exon – exon 
boundaries were filtered out, except for a breakpoint, ETV6-RP11-434C1.1, also located on 
chromosome arm 12p, which was not strictly a fusion transcript but a transcript produced 
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from an unannotated alternative promoter. This alternative promoter of ETV6 was specially 
considered based on the known oncogenic relevance of the ETS family of transcription 
factors (26). The final list of transcripts selected for experimental validation consisted of two 
inter-chromosomal and seven intra-chromosomal fusion transcript candidates (Figure 2, 
Table 1). Of the seven intra-chromosomal fusions, five included breakpoints with both 
partner genes located on chromosome arm 12p.
Technical and clinical validation of the fusion transcripts
We performed RT-PCR to validate the presence of the nine nominated fusion transcript 
breakpoints in the EC and ES cell lines investigated, and for further clinical evaluation in a 
series of IGCN and TGCTs. All nine nominated fusion transcripts were confirmed by RT-
PCR spanning the breakpoint. Successful Sanger sequences were produced from eight of 
these, confirming breakpoint sequences between the two gene pairs, and all found to use 
intact exon – exon boundaries (Supplementary Figure S1). The eight fusion transcripts as 
well as the alternative promoter usage of ETV6 all had intact open reading frames (ORFs), 
theoretically encoding functional proteins. The ORFs of five out of nine encode N-
terminally truncated proteins of the downstream partner gene, while three out of nine encode 
the full length coding sequence of the downstream partner. None of the fusion transcripts 
encode potential hybrid proteins with in-frame coding sequence from both intact partner 
proteins. However, one of the fusion transcripts, PPP6R3-DPP3, encodes an out-of-frame 
ORF encoding 198 amino acids.
Five of the fusion transcripts were only expressed in the originally nominated EC cell lines, 
and were thus considered private fusion events. The remaining four candidates were however 
found to be recurrently expressed in TGCT (Supplementary Table S4), and crucially, not in 
normal testicular parenchyma. The four recurrent candidates included the read-through 
between CLEC6A and CLEC4D, alternative promoter usage of ETV6, and two fusion 
transcripts both involving the first two exons of RCC1 as an upstream partner gene 
connected to HENMT1 and ABHD12B, located 80 Mbp apart on chromosome 1 and on 
chromosome 14 respectively. Expression of these recurrent transcripts was variable, with 
both strongly positive and weaker bands detected by agarose gel electrophoresis. For more 
accurate assessment of expression, we used qRT-PCR to quantify the expression level of 
each fusion transcript. All custom TaqMan assays were found to have efficiencies between 
80-90 %. Here, a total of 73 tissue samples and cell lines were tested. None of the recurrent 
transcripts were expressed in normal testicular parenchyma (n = 6). The read-through 
between CLEC6A and CLEC4D was found to be expressed in all subtypes of TGCT, as well 
as pre-malignant IGCN (6/6) and ES cell lines (3/3). However, only two of the four teratoma 
tissue samples showed expression of the read-through. The read-through was only detected 
in one (the placenta) of 20 normal tissues from the human body (Figure 3A). Alternative 
promoter usage of the ETV6 gene was predominantly detected in EC tissue samples and cell 
lines (75 % and 92 %, respectively; 6/8 and 12/13). Alternative promoter usage was also 
observed in ES cell lines (100 %; 3/3), seminoma (14 %; 1/7), Cc (100 %; 1/1) and YST 
(50 %; 2/4). None of the 20 included normal tissues expressed the alternative promoter of 
ETV6 (Figure 3B). The intrachromosomal fusion transcript RCC1-HENMT1 was widely 
expressed in all subtypes of TGCT, IGCN, ES cell lines, and in 6/20 normal tissue types 
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(spleen, esophagus, trachea, thyroid, thymus and skeletal muscle; Figure 3C). By contrast, 
the interchromosomal fusion transcript RCC1-ABHD12B was found expressed 
predominantly in EC tissue samples and cell lines (100 %) and in seminomas (86 %; 6/7). 
RCC1-ABHD12B was further detected in 67 % (4/6) IGCN, in one of four teratomas and in 
one of three ES cell lines. None of the tested tissue samples from sites of the human body 
showed expression of this fusion transcript (Figure 3D).
RCC1 involving fusion transcripts and alternative promoter usage in ETV6 are 
associated with undifferentiated subtypes of TGCT—Total RNA isolated from 
NTERA2 and 2102Ep cell lines treated with RA for 0, 3 and 7 days were included in the 
validation panel. The NTERA2 cell line has previously been shown to differentiate in culture 
when treated with morphogens such as RA (21). 2102Ep, on the other hand, does not 
differentiate upon in vitro treatment with RA and remains pluripotent (27). Intriguingly, 
qRT-PCR analyses of both fusion transcripts involving RCC1 revealed that expression 
decreased upon treatment with RA in NTERA2, but not in 2102Ep (Figure 4). The measured 
ΔΔCT was −3.9 and −3.0 between 0 and 7 days of RA treatment for RCC1-ABHD12B and 
RCC1-HENMT1 respectively. Additionally, expression of the ETV6 transcript involving the 
alternative promoter was silenced after 7 days of RA treatment (CT > 35; ΔΔCT of −6.8). 
Expression of the CLEC6A-CLEC4D read-through did not change significantly upon RA 
treatment in NTERA2. The expression of all fusion transcripts remained unchanged in the 
2102Ep cell line upon treatment with RA (Figure 4), in line with this cell line’s previously 
reported nonresponsiveness to RA treatment.
Linkage assays by ddPCR to identify coupling of fusion genes on the DNA-level
Because the two fusion transcripts involving RCC1 were recurrently expressed, and the two 
partner genes were not located close to RCC1, the possibility of genome-level 
rearrangements as a mechanism resulting in gene fusion was tested by ddPCR linkage 
analysis. For another two fusion genes EPT1-GUCY1A3 and PPP6R3-DPP3, expressed in 
the 833KE and NTERA2 cell lines respectively, DNA copy number data indicated a shift in 
the vicinity of all four genetic loci (data not shown).
To establish the integrity of DNA to be included in the linkage analyses, and as proof of 
concept, we performed a ddPCR milepost experiment. Here, multiplexed fluorescent 
TaqMan assays measured linkage 1 kb, 10 kb, 50 kb and 100 kb apart. DNA isolated by the 
AllPrep method from the NTERA2 cell line showed highest integrity, with 90 % linkage at 1 
kb, 52 % at 10 kb and 11 % at 50 kb (Supplementary Figure S2). No evidence of linkage 
was seen at 100 kb. DNA from the 833KE cell line and DNA isolated by phenol-chloroform 
from NTERA2 showed slightly lower linkage scores, indicating more highly degraded DNA 
(Supplementary Figure S2). After DNA fragmentation with the NspI restriction 
endonuclease, all linkage was substantially reduced, but some background levels remained 
(0 – 3.5 %; Supplementary Figure S2). Fusion gene linkage analysis of VTI1A-TCF7L2, 
previously reported to be caused by a deletion in the NCI-H508 cell line, showed that 
18.5 % of molecules are linked and contain both fusion partner targets (Figure 5). The 
interchromosomal fusion EPT1-GUCY1A3 and the intrachromosomal fusion PPP6R3-DPP3 
showed evidence of DNA-level linkage, with 15 and 18 % linkage rates respectively (Figure 
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5). However, we found no evidence for DNA-level linkage for the recurrently expressed 
fusions RCC1-ABHD12B and RCC1-HENMT (Figure 5). As a control experiment, we 
found that the DNA-level linkage in all tested samples was lost upon digesting the DNA 
with the restriction enzyme NspI.
Discussion
In this study, we have identified the presence of fusion genes and transcripts in TGCT. Nine 
novel fusion genes and transcripts are reported, of which RCC1-HENMT1, RCC1-
ABHD12B, CLEC6A-CLEC4D and alternative promoter usage of ETV6 are recurrently 
expressed in a significant number of clinical TGCT samples. Whereas these were detected 
only on the transcript level, two DNA-level fusions were identified, EPT1-GUCY1A3 and 
PPP6R3-DPP3, although these were privately expressed by individual EC cell lines.
The non-synonymous mutation rate in TGCTs has recently been found to be low, on a scale 
similar to pediatric cancers (14–16). The fact that few genes are recurrently mutated 
indicates that other molecular mechanisms are responsible for the development of TGCT. 
The genomes of TGCTs are generally aneuploid, with several recurrent gains and losses of 
chromosomal material (10,28). Structural rearrangements in these aneuploid tumors are 
known from cytogenetic banding analyses, and i(12p) is found in the majority of TGCT 
(9,29,30). Cases without i(12p) often have gain of parts of 12p material, and/or extra copies 
of the whole of chromosome 12 (31). Gain or loss of chromosomal material not only leads to 
increase or loss of gene copies and subsequent expression changes, but can also introduce 
genomic rearrangements that form fusion genes. The nine novel fusion genes and transcripts 
found in this study, all consisting of intact ORFs which potentially encode full-length or N-
terminally truncated proteins, suggest that fusion genes play an important role, and may be 
drivers for the malignant development of TGCTs. CLEC6A and CLEC4D, found to be 
involved in a read-through expressed in a high number of clinical TGCT samples, and ETV6 
with a novel alternative promoter, are all located on chromosome arm 12p. In addition, all 
genes involved in the CD9-ANO2, TSPAN9-FOXJ2 and TSPAN9-GUCY2C fusion 
transcripts, expressed in the 2102Ep EC cell line, are located on 12p. These findings indicate 
that 12p is a dynamic region in TGCTs, and that gain of 12p material may be associated with 
expression of recurrent fusion transcripts and transcript variants.
Both fusion transcripts that involved RCC1 and the alternative promoter usage of ETV6 are 
overrepresented in undifferentiated histological subtypes of TGCT, and show substantially 
reduced expression in the NTERA2 EC cell line upon RA-induced differentiation in vitro. 
This indicates that they are all associated with the pluripotent phenotype. ETV6 (ets variant 
6) encodes a transcription factor of the ETS family, a family of transcription factors that are 
frequently involved as fusion gene partners in cancer. ETV6 itself has repeatedly been 
reported as a fusion gene partner in hematological malignancies (32). In fact, a chromosomal 
rearrangement (4;12)(q11-q12;p13) found in cases of acute myeloid leukemia fuses CHIC2 
(exon 1-3) and ETV6 (exon 2-8) using the same breakpoint of ETV6 as the one identified 
here connected to the newly identified alternative promoter sequence (33,34). RCC1 
(Regulator of chromosome condensation 1) has important functions in the cell cycle and acts 
as a guanine nucleotide exchange factor (GEF) for the RAS homologue RAN (35). However, 
Hoff et al. Page 9
Cancer Res. Author manuscript; available in PMC 2016 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
the fusion transcripts involving RCC1 only includes the two first non-coding exons in the 5′ 
UTR of RCC1 connected to either HENMT1 or ABHD12B located 80 Mb downstream on 
chromosome 1 and on chromosome 14, respectively. The long genomic distance between the 
partner genes suggests that these fusion transcripts are not expressed as a result of a read-
through mechanism (36). To investigate if the fusion transcripts involving RCC1 were 
caused by genomic rearrangements, we applied linkage analysis using multiplexed 
fluorescent PCR assays with ddPCR. To our knowledge, this approach has not been used 
previously to detect rearrangements of genes resulting in fusion genes. However, linkage 
analysis with ddPCR has been proven successful in showing the arrangement of the Killer-
cell immunoglobulin-like receptor gene complex and in chromosomal phasing (37,38). We 
found no indication of DNA-level linkage for the partner genes of the RCC1 fusion 
transcripts. However, the partner genes of EPT1-GUCY1A3 and PPP6R3-DPP3, which also 
had indications of chromosomal breakpoints from DNA copy number data, were found to be 
linked at the DNA-level, indicating bona-fide genomic rearrangements in their respective 
cell lines, 833KE and NTERA2. The absence of linked partner genes of the RCC1 fusions, 
implies that these fusion transcripts are expressed as the result of post-transcriptional 
mechanisms, such as trans-splicing (39). However, we cannot rule out chromosomal 
rearrangements as an underlying cause of the RCC1 fusion transcripts, since only a 
proportion of the input DNA in our assay consisted of DNA fragments longer than 50 kb, 
and none more than 100 kb in length. A chromosomal rearrangement resulting in a fusion 
gene may include intronic regions that are longer than these DNA fragments. Such 
rearrangements will be missed by ddPCR linkage analysis. For optimal sensitivity, linkage 
analysis should be carried out on DNA samples isolated by protocols that maintain long 
DNA molecules intact.
Expression of the interchromosomal RCC1-ABHD12B fusion transcript and transcripts 
involving the alternative promoter of ETV6 was not detected in normal testis or other normal 
tissue samples from 20 different human organs. Also, expression of CLEC6A-CLEC4D was 
only observed in normal tissue from the placenta, indicating that it may be specifically 
expressed in adult male TGCT. These molecules are therefore highly specific for TGCTs in 
a stemness setting, and could prove to have important roles for TGCT malignant 
transformation, as well as biomarkers for TGCT disease. Diagnosis of TGCT through 
sensitive detection of these molecules in excreted body fluids such as seminal fluid or serum 
could have clinical potential (40).
In conclusion, to our knowledge, we present here the first fusion genes to be described in 
TGCT, including recurrent expression of RCC1 involving fusions and alternative promoter 
usage of the ETV6 gene, both associated with the pluripotency phenotype. These transcript 
variants may be important drivers of malignancy, and could potentially serve as diagnostic 
markers in the clinic.
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Figure 1. Filtering pipeline of nominated fusion transcripts
The identified fusion transcripts were filtered in a successive manner, resulting in nine final 
fusion transcripts that were experimentally validated.
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Figure 2. TGCT fusion transcripts identified by RNA-sequencing
All the nine novel transcripts have fusion breakpoints at intact exon-exon boundaries, except 
for the ETV6 gene, where a new alternative promoter (exon 1A) was connected to exon 2. 
The breakpoint boundaries are indicated between upstream partner gene (blue) and 
downstream partner gene (orange). Full height of boxes of solid color represent predicted 
coding regions of original partner genes. Arrows mark the start codons of fusion transcript 
ORFs identified by the ORF finder at the National Centre for Biotechnology Information. 
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Red lines mark the stop codons of upstream partner gene ORFs. The genomic coordinates 
indicate the exact coordinate of the fusion breakpoint in the specific partner gene.
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Figure 3. Fusion transcripts and alternative promoter usage of ETV6 recurrently expressed in 
TGCT
Quantitative RT-PCR of recurrent fusion transcripts reported in CT values normalized to 
median CT values of endogenous controls, with higher expression corresponding to lower 
CT values. Transcripts were considered absent for CT > 35. Samples are grouped together 
according to histological subtype and ordered with increasing expression A. The read-
through CLEC6A-CLEC4D was expressed in all subtypes of TGCTs and also in the pre-
malignant IGCN samples, but not in tissue from normal testis. From normal tissue samples 
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from 20 different human organs only placenta expressed CLEC6A-CLEC4D. B. The ETV6 
transcript with an alternative exon 1 was expressed mainly in undifferentiated EC tumor 
samples and cell lines. It was also found to be expressed in the ES cell lines, in 1/6 
seminomas, 1 choriocarcinoma and 2/3 YSTs. None of the samples from normal testis or 
normal human organs expressed this novel transcript. C. The intrachromosomal fusion 
transcript RCC1-HENMT1 was expressed in all IGCN and TGCT samples, except for 1 
YST. Also, the fusion transcript was detected in 3/3 ES cell lines and in 5/20 samples from 
normal human tissue. D. The interchromosomal fusion transcript RCC1-ABHD12B was 
expressed in 4/6 IGCN samples, undifferentiated subtypes of TGCTs including 5/6 
seminomas, and all EC cell lines and samples. Also, 1/3 ES cell lines and 1/4 teratomas 
expressed the fusion transcript. None of the normal testis samples or normal human tissues 
expressed the fusion transcript.
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Figure 4. Fusions involving RCC1 and the ETV6 alternative promoter transcripts are down-
regulated upon treatment with RA
Quantitative RT-PCR results for the fusion transcripts involving RCC1, the ETV6 alternative 
promoter and CLEC6A-CLEC4D, in 2102Ep and NTERA2 cells treated with RA for 0, 3 
and 7 days. Expression is reported as CT values normalized to median CT values of 
endogenous controls. The lighter to darker color gradient represents an in vitro 
undifferentiated to differentiated state. No clear patterns of expression are seen in the 
2102Ep cell line, except for a general lower level of expression at 3 days of RA treatment. 
NTERA2 has reduced expression of RCC1-HENMT1, RCC1-ABHD12B and ETV6 
alternative promoter after 3 and 7 days.
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Figure 5. EPT1-GUCY1A3 and PPP6R3-DPP3 are chromosomally rearranged
DNA-level linkage of fusion partner genes, reported in percent linkage from ddPCR 
analysis, confirmed a genomic rearrangement underlying the known VTI1A-TCF7L2 fusion. 
The fusions EPT1-GUCY1A3 and PPP6R3-DPP3 were shown to be linked on the DNA-
level in 833KE and NTERA2, respectively. No DNA-level linkage was detected for the 
partner genes involved in the RCC1 fusion transcripts. Linkage was undetected after 
fragmentation of DNA with the NspI endonuclease.
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Table 1
Nominated breakpoints from deFuse analysis of RNA-sequencing data
Nine breakpoints remained after heuristic filtering steps of initial candidates. Of these, CLEC6A-CLEC4D 
was nominated in all three EC cell lines. Breakpoints are listed according to the cell lines in which they were 
identified and with ascending genomic distance between the two partner genes. Presence of ORFs was 
determined using the ORF finder at the National Centre for Biotechnology Information (NCBI).
Cell line Gene A Gene B Chromosome bands Distance (kb) defuse score ORF
CLEC6A CLEC4D 12p13.31 12p13.31 31 0.99 Y
CD9 ANO2 12p13.31 12p13.31 253 0.97 Y
TSPAN9 FOXJ2 12p13.33-p13.32 12p13.31 4,790 0.97 Y
2102Ep TSPAN9 GUCY2C 12p13.33-p13.32 12p13.1-p12.3 11,370 0.94 Y
CLEC6A CLEC4D 12p13.31 12p13.31 31 0.99 Y
RCC1 HENMT1 1p35.3 1p13.3 80,325 0.92 Y
833KE EPT1 GUCY1A3 2p23.3 4q32.1 0.97 Y
CLEC6A CLEC4D 12p13.31 12p13.31 31 0.83 Y
ETV6 RP11-434C1.1* 12p13.2 12p13.2 59 0.81 Y
PPP6R3 DPP3 11q13.2-13.3 11q13.2 1,951 0.82 Y
NTERA2 RCC1 ABHD12B 1p35.3 14q22.1 0.98 Y
*RP11-434C1.1 was nominated as a partner to ETV6, located 85kb downstream. However, visual inspection revealed that the breakpoint localized 
to non-coding regions between these two genes and reflects an alternative promoter of ETV6.
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